トップページに戻る
Publication

2012年

  1. VEGF -634C/G Genotype is Predictive of Long-term Survival after Treatment with a Definitive 5-Fluorouracil/cisplatin-based Chemoradiotherapy in Japanese Patients with Esophageal Squamous Cell Carcinoma.
    Tamura T, Kuwahara A, Yamamori M, Nishiguchi K, Nakamura T, Okuno T, Miki I, Manabe Y, Sakaeda T.
    Int J Med Sci. 9: 833-837 (2012).
  2. THRB Genetic Polymorphisms Can Predict Severe Myelotoxicity after Definitive Chemoradiotherapy in Patients with Esophageal Squamous Cell Carcinoma.
    Miki I, Nakamura T, Kuwahara A, Yamamori M, Nishiguchi K, Tamura T, Okuno T, Omatsu H, Mizuno S, Hirai M, Azuma T, Sakaeda T.
    Int J Med Sci. 9: 748-756 (2012).
  3. Potential tumor markers of renal cell carcinoma: α-enolase for postoperative follow-up and galectin-1 and galectin-3 for primary detection.
    Kaneko N, Gotoh A, Okamura N, Matsuo E, Terao S, Watanabe M, Yamada Y, Hamami G, Nakamura T, Nishimura O.
    Int J Urol.in press. (2012).
  4. Cytotoxicity of 15-Deoxy-Δ12,14-prostaglandin J2 through PPARγ-independent Pathway and the Involvement of the JNK and Akt Pathway in Renal Cell Carcinoma.
    Fujita M, Tohji C, Honda Y, Yamamoto Y, Nakamura T, Yagami T, Yamamori M, Okamura N.
    Int J Med Sci. 9: 555-566 (2012).
  5. Mycophenolate mofetil: fully utilizing its benefits for GvHD prophylaxis.
    Minagawa K, Yamamori M, Katayama Y, Matsui T.
    Int J Hematol. 96: 10-25 (2012).
  6. Involvement of the mevalonate pathway in anti-proliferative effect of zoledronate on renal cell carcinoma, ACHN.
    Fujita M, Tohi M, Sawada K, Yamamoto Y, Nakamura T, Yagami T, Yamamori M, Okamura N.
    Oncol Rep. 27: 1371-1376 (2012).
  7. Treatment schedule-dependent effect of 5-fluorouracil and platinum derivatives in colorectal cancer cells.
    Takara K, Fujita M, Minegaki T, Yamamoto K, Takahashi M, Yokoyama T, Okumura K.
    Eur J Pharm Sci. 45: 272-281 (2012).
  8. がん化学療法レジメンの違いによる制吐療法の評価 −VASを用いた評価−．
    柳井美奈、山下典子、山森元博、西川翠、辰己純代、富田寿彦、三輪洋人、木村健、岡村昇
    医療薬学     38: 609-616 (2012).
  9. 末梢静脈栄養輸液中におけるインスリンの安定性に関する検討．
    河野えみ子、泉伯枝、安永浩子、中村奈緒美、松本絵麻、奥山悦子、新崎孝夫、三箇山宏樹、岡村昇
    静脈経腸栄養     27: 739-745 (2012).

2011年

  1. Cytotoxicity of troglitazone through PPARγ-independent pathway and p38 MAPK pathway in renal cell carcinoma.
    Fujita M, Yagami T, Fujio M, Tohji C, Takase K, Yamamoto Y, Sawada K, Yamamori M, Okamura N.
    Cancer Lett. 312: 219-227 (2011).
  2. Effects of plasma concentrations of 5-fluorouracil on long-term survival after treatment with a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma.
    Kuwahara A, Yamamori M, Kadoyama K, Nishiguchi K, Nakamura T, Miki I, Tamura T, Okuno T, Omatsu H, Sakaeda T.
    J Exp Clin Cancer Res.30: 94 (2011).
  3. Hypersensitivity reactions to anticancer agents: Data mining of the public version of the FDA adverse event reporting system, AERS.
    Kadoyama K, Kuwahara A, Yamamori M, Brown JB, Sakaeda T, Okuno Y.
    J Exp Clin Cancer Res.30: 93 (2011).
  4. Pharmacokinetics-based optimal dose prediction of donor source-dependent response to mycophenolate mofetil in unrelated hematopoietic cell transplantation.
    Wakahashi K, Yamamori M, Minagawa K, Ishii S, Nishikawa S, Shimoyama M, Kawano H, Kawano Y, Kawamori Y, Sada A, Matsui T, Katayama Y.
    Int J Hematol.94: 193-202 (2011).
  5. Effects of bolus injection of 5-fluorouracil on steady-state plasma concentrations of 5-fluorouracil in with advanced colorectal cancer.
    Tamura T, Kuwahara A, Kadoyama K, Yamamori M, Nishiguchi K, Inokuma T, Takemoto Y, Chayahara N, Okuno T, Miki I, Fujishima Y, Sakaeda T.
    Int J Med Sci. 8: 406-412 (2011).
  6. 15-Deoxy-Δ12,14-prostaglandin J2 enhanced the anti-tumor activity of camptothecin against renal cell carcinoma independently of topoisomerase-II and PPARγ pathways.
    Yamamoto Y, Fuita M, Koma H, Yamamori M, Okamura N, Yagami T.
    Biochem Biophys Res Commun. 410: 563-567 (2011).
  7. Proteomic identification of protein targets for 15-deoxy-Δ12,14-prostaglandin J2 in neuronal plasma membrane.
    Yamamoto Y, Takase K, Kishino J, Fujita M, Okamura N, Sakaeda T, Fujimoto M, Yagami T.
    PLoS One. 6: e17552 (2011).
  8. Risk factors for oxaliplatin-induced hypersensitivity reactions in Japanese patients with advanced colorectal cancer
    Seki K, Senzaki K, Tsuduki Y, Ioroi T, Fujii M, Yamauchi, H, Shiraishi Y, Nakata I, Nishiguchi K, Matsubayashi T, Takakubo Y, Okamura N, Yamamori M, Tamura T, Sakaeda T.
    Int J Med Sci. 8: 210-215 (2011).
  9. VEGF 936C>T is predictive of threshold retinopathy of prematurity in Japanese infants with a 30-week gestational age or less.
    Yagi M, Yamamori M, Morioka I, Yokoyama N, Honda S, Negi A, Nakamura T, Okamura N, Okumura K, Sakaeda T, Matsuo M.
    Res Rep Neonatol. 1: 5-11 (2011).
  10. 実務実習生の医薬品情報リテラシー向上を目的とした医薬品情報実習の効果.
    谷藤亜希子、田中健太、平野剛、岡村昇、平井みどり
    医薬品情報学     13: 95-102 (2011).
  11. バンコマイシン、アルベカシンTDM業務におけるCompartment Model選択のPK/PDパラメータに対する影響.
    加藤克洋、池田桂子、岡村昇
    日病薬誌     47: 1029-1032 (2011).
  12. 緊急入院患者における入院時薬歴管理の重要性と課題−予定入院と比較して−.
    續木康夫、藤井大和、松本信彦、竹内智恵、岩槻瑠美、宮井絢美、本田富得、竹村契二、古川哲也、中村慶、和田洋忠、岡村昇
    医療薬学     37: 41-48 (2011).

2010年

  1. Association of genetic polymorphisms with hepatotoxicity in patients with childhood acute lymphoblastic leukemia or lymphoma.
    Horinouchi M, Yagi M, Imanishi H, Mori T, Yanai T, Hayakawa A, Takeshima Y, Hijioka M, Okamura N, Sakaeda T, Matsuo M, Okumura K, Nakamura T.
    Pediatr Hematol Oncol. 27: 344-354 (2010).
  2. TNFRSF1B A1466G genotype is predictive of clinical efficacy after treatment with a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma.
    Kuwahara A, Yamamori M, Fujita M, Okuno T, Tamura T, Kadoyama K, Okamura N, Nakamura T, Sakaeda T.
    J Exp Clin Cancer Res. 29: 100 (2010).
  3. Diabetes-accelerated memory dysfunction via cerebrovascular inflammation and Abeta deposition in an Alzheimer mouse model with diabetes..
    Takeda S, Sato N, Uchio-Yamada K, Sawada K, Kunieda T, Takeuchi D, Kurinami H, Shinohara M, Rakugi H, Morishita R..
    Proc Natl Acad Sci USA 107: 7036-7041 (2010).
  4. Effect of CPS1 4217C>A genotype on valproic acid-induced hyperammonemia.
    Yagi M, Nakamura T, Okizuka Y, Oyazato Y, Kawasaki Y, Tsuneishi S, Sakaeda T, Matsuo M, Okumura K, Okamura N.
    Pediatr Int. 52: 744-748 (2010)    . 平成22年度 イーライリリーアワード受賞論文
  5. Fibroblast growth factor 2 induces apoptosis in the early primary culture of rat cortical neurons.
    Yagami T, Takase K, Yamamoto Y, Ueda K, Takasu N, Okamura N, Sakaeda T, Fujimoto M.
    Exp Cell Res. 316 : 2278-90 (2010).
  6. Sustained delivery of lidocaine into the cochlea using poly lactic/glycolic acid microparticles.
    Horie RT, Sakamoto T, Nakagawa T, Tabata Y, Okamura N, Tomiyama N, Tachibana M, Ito J.
    Laryngoscope. 120: 377-83 (2010)    .
  7. Stability of gabexate mesilate products: Influence of the addition of mannitol.
    Sakurai M, Abe H, Okamura N, Inoue Y, Akiyoshi T, Matsuyama K, Uchida T, Otsuka M.
    Biomed Mater Eng. 20: 13-20 (2010)    .
2009年
  1. Effect of corticosteroids on phlebitis induced by intravenous infusion of antineoplastic agents in rabbits.
    Kohno E, Murase S, Matsuyama K, Okamura N.
    Int J Med Sci. 6: 218-23 (2009).
  2. The potential of vitamin K3 as an anticancer agent against breast cancer that acts via the mitochondria-related apoptotic pathway.
    Akiyoshi T, Matzno S, Sakai M, Okamura N, Matsuyama K.
    Cancer Chemother Pharmacol. 65: 143-50 (2009).
  3. Effects of ABCB1 3435C>T genotype on serum levels of cortisol and aldosterone in women with normal menstrual cycles.
    Nakamura T, Okamura N, Yagi M, Omatsu H, Yamamori M, Kuwahara A, Nishiguchi K, Horinouchi M, Okumura K, Sakaeda T.
    Genet Mol Res. 8: 397-403 (2009).
  4. Effects of acid and lactone forms of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on the induction of MDR1 expression and function in LS180 cells.
    Yamasaki D, Nakamura T, Okamura N, Kokudai M, Inui N, Takeuchi K, Watanabe H, Hirai M, Okumura K, Sakaeda T.
    Eur J Pharm Sci. 37: 126-32 (2009).
  5. Expression of macrophage metalloelastase (MMP-12) in podocytes of hereditary nephrotic mice (ICGN strain).
    Uchio K, Sawada K, Manabe N.
    J Vet Med Sci. 71: 305-312 (2009)
  6. Elevation of plasma beta-amyloid level by glucose loading in Alzheimer mouse models.
    Takeda S, Sato N, Uchio-Yamada K, Sawada K, Kunieda T, Takeuchi D, Kurinami H, Shinohara M, Rakugi H, Morishita R.
    Biochem Biophys Res Commun. 385: 193-197 (2009)
  7. 後期高齢者におけるバンコマイシンのAUC/MICとCRP低下率の相関
    加藤克洋、池田桂子、岡村昇
    日病薬誌，45, 1095-1098 (2009)
  8. アルベカシン硫酸塩のピーク値に影響を与える因子
    池田桂子，池田智絵，加藤克洋，冨山直樹，松野純男，松山賢治，岡村昇
    医療薬学，35, 701-705 (2009).
2008年
  1. Quantitative proteomic analysis to discover potential diagnostic markers and therapeutic targets in human renal cell carcinoma.
    Okamura N, Masuda T, Gotoh A, Shirakawa T, Terao S, Kaneko N, Suganuma K, Watanabe M, Matsubara T, Seto R, Matsumoto J, Kawakami M, Yamamori M, Nakamura T, Yagami T, Sakaeda T, Fujisawa M, Nishimura O, Okumura K.
    Proteomics. 8: 3194-203 (2008).
  2. Role of Na+/L-carnitine transporter (OCTN2) in renal handling of pivaloylcarnitine and valproylcarnitine formed during pivalic acid-containing prodrugs and valproic acid treatment.
    Ohnishi S, Okamura N, Sakamoto S, Hasegawa H, Norikura R, Kanaoka E, Takahashi K, Horie K, Sakamoto K, Baba T.
    Drug Metab Pharmacokinet. 23: 293-303 (2008).
  3. Reversal effects of Ca2+ antagonists on multidrug resistance via down-regulation of MDR1 mRNA.
    Komoto C, Nakamura T, Yamamori M, Ohmoto N, Kobayashi H, Kuwahara A, Nishiguchi K, Takara K, Tanigawara Y, Okamura N, Okumura K, Sakaeda T.
    Kobe J Med Sci. 53: 355-63 (2008).
  4. Three-dimensional, but not two-dimensional, culture results in tumor growth enhancement after exposure to anticancer drugs.
    Komoto C, Nakamura T, Ohmoto N, Kobayashi H, Yagami T, Nishiguchi K, Iwaki K, Kuwahara A, Yamamori M, Okamura N, Okumura K, Sakaeda T.
    Kobe J Med Sci. 53: 335-43 (2008).
  5. Methods of preventing vinorelbine-induced phlebitis: an experimental study in rabbits.
    Kohno E, Murase S, Nishikata M, Okamura N, Matzno S, Kuwahara T, Matsuyama K.
    Int J Med Sci. 5: 218-23 (2008).
  6. VEGF G-1154A is predictive of severe acute toxicities during chemoradiotherapy for esophageal squamous cell carcinoma in Japanese patients.
    Sakaeda T, Yamamori M, Kuwahara A, Hiroe S, Nakamura T, Okumura K, Okuno T, Miki I, Chayahara N, Okamura N, Tamura T.
    Ther Drug Monit. 30: 497-503 (2008).
  7. VEGF T-1498C polymorphism, a predictive marker of differentiation of colorectal adenocarcinomas in Japanese.
    Yamamori M, Taniguchi M, Maeda S, Nakamura T, Okamura N, Kuwahara A, Iwaki K, Tamura T, Aoyama N, Markova S, Kasuga M, Okumura K, Sakaeda T.
    Int J Med Sci. 5: 80-6 (2008).
  8. The possibility of simvastatin as a chemotherapeutic agent for all-trans retinoic acid-resistant promyelocytic leukemia.
    Tomiyama N, Matzno S, Kitada C, Nishiguchi E, Okamura N, Matsuyama K.
    Biol Pharm Bull. 31: 369-74 (2008).
  9. Considerations on prevention of phlebitis and venous pain from intravenous prostaglandin E1 administration by adjusting solution pH: in vitro manipulations affecting pH.
    Kohno E, Nishikata M, Okamura N, Matsuyama K.
    Yakugaku Zasshi. 128: 111-5 (2008).
  10. FOLFOX療法施行に伴うアレルギー反応に関する多施設共同研究
    関恭子、先崎健造、續木康夫、五百蔵武士、藤井道子、山内寛子、白石幸成、中多泉、西口工司、松林照久、高久保佳秀、岡村昇、栄田敏之
    医療薬学，34, 919-926 (2008).
2007年
  1. IL-1beta genotype-related effect of prednisolone on IL-1beta production in human peripheral blood mononuclear cells under acute inflammation.
    Markova S, Nakamura T, Makimoto H, Ichijima T, Yamamori M, Kuwahara A, Iwaki K, Nishiguchi K, Okamura N, Okumura K, Sakaeda T.
    Biol Pharm Bull. 30: 1481-7 (2007).
  2. Favorable genetic polymorphisms predictive of clinical outcome of chemoradiotherapy for stage II/III esophageal squamous cell carcinoma in Japanese.
    Okuno T, Tamura T, Yamamori M, Chayahara N, Yamada T, Miki I, Okamura N, Kadowaki Y, Shirasaka D, Aoyama N, Nakamura T, Okumura K, Azuma T, Kasuga M, Sakaeda T.
    Am J Clin Oncol. 30: 252-7 (2007).
  3. Knock-down of sorcin induces up-regulation of MDR1 in HeLa cells.
    Kawakami M, Nakamura T, Okamura N, Komoto C, Markova S, Kobayashi H, Hashimoto N, Okumura K, Sakaeda T.
    Biol Pharm Bull. 30: 1065-73 (2007).
  4. Glucuronidation converting methyl 1-(3,4-dimethoxyphenyl)-3-(3-ethylvaleryl)-4-hydroxy-6,7,8-trimethoxy-2-naphthoate (S-8921) to a potent apical sodium-dependent bile acid transporter inhibitor, resulting in a hypocholesterolemic action.
    Sakamoto S, Kusuhara H, Miyata K, Shimaoka H, Kanazu T, Matsuo Y, Nomura K, Okamura N, Hara S, Horie K, Baba T, Sugiyama Y.
    J Pharmacol Exp Ther. 322: 610-8 (2007).
  5. Genetic polymorphisms associated with adverse events and elimination of methotrexate in childhood acute lymphoblastic leukemia and malignant lymphoma.
    Imanishi H, Okamura N, Yagi M, Noro Y, Moriya Y, Nakamura T, Hayakawa A, Takeshima Y, Sakaeda T, Matsuo M, Okumura K.
    J Hum Genet. 52: 166-71 (2007).
  6. Cyclosporineからsirolimusへの切り替えに際し，sirolimus血中濃度の一過性上昇を認めた症例
    中村任，五百蔵武士，大松秀明，山下和彦，白木孝，堀之内正則，西口工司，福本巧，具英成，岡村昇，角山圭一，奥村勝彦，栄田敏之
    TDM研究，24: 98-103 (2007).